Home › Calculator › LABFF Dividend Calculator 2026
LABFF DRIP Calculator & Dividend Yield 2026
1.63% YieldHealthcareLaboratorios Farmaceuticos Rovi, S.A. · OTC
Price: $67.17 · Annual div: $1.10/share · Frequency: annual · Payout ratio: 40% · Ex-div: 2026-07-14
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When LABFF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
LABFF Dividend History — Last 9 Payments
| Ex-Dividend Date | Payment Date | Amount / Share | TTM Yield | Stock Price |
|---|---|---|---|---|
| 2026-07-14Latest | 2026-07-15 | $1.0963 | 2.41% | $90.61 |
| 2025-07-15 | 2025-07-16 | $1.0864 | 1.20% | $90.61 |
| 2024-07-08 | 2024-07-10 | $1.2937 | 1.43% | $90.61 |
| 2023-07-03 | 2023-07-05 | $1.5166 | 5.16% | $51.10 |
| 2022-07-05 | 2022-07-07 | $1.1201 | 5,181.07% | $0.03 |
| 2021-07-06 | 2021-07-07 | $0.4342 | 0.64% | $67.78 |
| 2019-07-02 | 2019-07-04 | $0.0730 | — | — |
| 2018-07-03 | 2018-07-05 | $0.1139 | — | — |
| 2017-07-03 | 2017-07-05 | $0.1685 | — | — |
About Laboratorios Farmaceuticos Rovi, S.A. (LABFF) — Dividend Analysis 2026
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical firm actively involved in the discovery, creation, manufacturing, and commercialization of medicinal products. Its market presence extends across Spain, the European Union, OECD nations, and other international territories. Beyond its proprietary portfolio, Rovi also distributes pharmaceutical offerings under license from other companies. Rovi's diverse product lineup addresses several critical health conditions. Key offerings include Hibor and Becat (an Enoxaparin biosimilar), both low-molecular-weight heparins employed in preventing and managing venous thromboembolic disorders. Neparvis targets symptomatic chronic heart failure with reduced ejection fraction in adults. For hypercholesterolemia, the company offers Absorcol, Vytorin, and Orvatez. Respiratory ailments like chronic obstructive pulmonary diseases (COPD) are treated with long-acting bronchodilators such as Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is prescribed for men experiencing moderate to severe storage and voiding symptoms due to benign prostatic hyperplasia (BPH) who have not responded sufficiently to single-drug therapies. Additionally, Medikinet and Medicebrán provide treatment for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent populations. The firm also supplies a range of specialized hospital products for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventional procedures, Multihance and Prohance for MRI, and Sonovue for ultrasound examinations. Furthermore, Rovi provides advanced contrast injection systems, including EmpowerCTA+, EmpowerMR, and CT Exprès, along with their associated disposable components. Its portfolio extends to over-the-counter (OTC) pharmaceutical products. Moreover, Rovi offers contract development and manufacturing organization (CDMO) services to external businesses, producing pharmaceuticals in diverse forms such as prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi caters to a broad spectrum of healthcare stakeholders, encompassing wholesalers, physicians, nurses, pharmacists, and directly, patients. A notable partnership exists with Moderna, Inc., where Rovi is involved in the manufacturing of mRNA COVID-19 vaccine candidates. Established in 1946 and headquartered in Madrid, Spain, Laboratorios Farmaceuticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
Similar dividend stocks to LABFF
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full LABFF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open LABFF position with:
🌍 LABFF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold LABFF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1.63% | -1.17% | $163 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.39% | -1.41% | $139 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.30% | -1.50% | $130 / yr |
| 🇬🇧 UK ISA | 0% | 1.63% | -1.17% | $163 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.49% | -1.31% | $149 / yr |
| 🇨🇦 TFSA | 0% | 1.63% | -1.17% | $163 / yr |
| 🇨🇦 CA Taxable | 25% | 1.22% | -1.58% | $122 / yr |
| 🇦🇺 Super (pension) | 15% | 1.39% | -1.41% | $139 / yr |
| 🇦🇺 AU Taxable | 30% | 1.14% | -1.66% | $114 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.20% | -1.60% | $120 / yr |
| 🇫🇷 FR Taxable | 30% | 1.14% | -1.66% | $114 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 LABFF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $1.10/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 LABFF Dividend Payment Schedule
LABFF pays annually — 1 payment per year.
📊 LABFF vs Healthcare Benchmarks
How LABFF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LABFF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ LABFF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LABFF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) is currently trading at $67.17, trading near its 52-week low. The current dividend yield is 1.63% based on an annual payout of $1.10 per share.
LABFF (Laboratorios Farmaceuticos Rovi, S.A.) — 1.63% Dividend Yield Analysis
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) is a healthcare stock currently trading at $67.17 with a dividend yield of 1.63%. It pays an annual dividend of $1.10 per share. The payout ratio of 40% suggests the dividend is well-covered by earnings. Over the past 5 years, LABFF has grown its dividend at a compound annual rate of 39.8%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest LABFF News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
How investors use the LABFF dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.